OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?

• Keith C. Ferdinand,
• Asaad Nakhle

Affiliations

Keith C. Ferdinand

Corresponding author at: 1430 Tulane Ave, Mail Code 8048, New Orleans, LA 70112, United States of America.; Tulane University School of Medicine, Section of Cardiology, 1430 Tulane Ave, New Orleans, LA 70112, United States of America

Asaad Nakhle

Tulane University School of Medicine, Section of Cardiology, 1430 Tulane Ave, New Orleans, LA 70112, United States of America